Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

About the study

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
Adequate bone marrow, kidney and liver function
Performance status of 0 or 1.
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

EXCLUSION CRITERIA

Exclusion Criteria:

•Prior treatment targeting ILT3.

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details

Contition

Melanoma,Pancreatic Cancer,Breast Cancer,Gastric Cancer,Non-small Cell Lung Cancer,Cervical Cancer,Endocervical Cancer,Squamous Cell Carcinoma of Head and Neck,Bladder Urothelial Cancer,Colorectal Carcinoma,Esophageal Cancer,Ovarian Cancer,Renal Cell Carcinoma,Prostate Cancer,Mesothelioma,Cholangiocarcinoma

Age (in years)

18+

Phase

Phase 1

Participants needed

Est. Completion Date

Dec 31, 2024

Treatment type

Interventional

Sponsor

NGM Biopharmaceuticals, Inc

ClinicalTrials.gov identifier

NCT05215574

Study number

831-IO-101

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?